


PHARMACEUTICAL 2019



Enveric Biosciences Inc. Rank 257 of 363





PHARMACEUTICAL 2019



Enveric Biosciences Inc. Rank 257 of 363

The relative strengths and weaknesses of Enveric Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enveric Biosciences Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 131% points. The greatest weakness of Enveric Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is 1.4%, being 35% points below the market average of 37%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 10,061 |
| Cost of Goods Sold | 34,015 |
| Intangible Assets | 19,508 |
| Liabilities, Current | 14,689 |
| Liabilities, Non-Current | 4,189 |
| Other Assets | 9.4 |
| Other Compr. Net Income | -2,533 |
| Other Expenses | 11,684 |
| Other Liabilities | 0 |
| Other Net Income | -3,403 |
| Other Revenues | 42,998 |
| Property and Equipment | 59 |
| Research and Development | 0 |
| Selling, General and Administrative Expense | 10,795 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 29,637 |
| Liabilities | 18,878 |
| Expenses | 56,493 |
| Revenues | 42,998 |
| Stockholders Equity | 10,759 |
| Net Income | -16,898 |
| Comprehensive Net Income | -18,164 |
| Economic Capital Ratio | 1.4% |

